QIPT · As filed with the SEC
Quipt Home Medical income statement, by fiscal year
The statement as Quipt Home Medical presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
CONSOLIDATED STATEMENTS OF INCOME (LOSS) · USD, except per-share amounts
| USD, except per-share amounts | FY2025 Year ended Sep 30, 2025 | FY2024 Year ended Sep 30, 2024 | FY2023 Year ended Sep 30, 2023 | FY2022 Year ended Sep 30, 2022 | FY2021 Year ended Sep 30, 2021 | FY2020 Year ended Sep 30, 2020 |
|---|---|---|---|---|---|---|
| Revenue | ||||||
| Rentals of medical equipment | 100,108,000 | 94,308,000 | — | — | — | — |
| Sales of medical equipment and supplies | 145,251,000 | 151,607,000 | — | — | — | — |
| Total revenues | 245,359,000 | 245,915,000 | — | — | — | — |
| Cost of inventory sold | 68,182,000 | 68,925,000 | — | — | — | — |
| Operating expenses | 125,457,000 | 122,542,000 | — | — | — | — |
| Right-of-use operating lease amortization and interest | 6,434,000 | 5,974,000 | — | — | — | — |
| Depreciation | 39,429,000 | 38,490,000 | — | — | — | — |
| Amortization of intangible assets | 6,053,000 | 6,091,000 | — | — | — | — |
| Stock-based compensation | 4,035,000 | 2,484,000 | — | — | — | — |
| Acquisition-related costs | 817,000 | 401,000 | — | — | — | — |
| Gain on disposals of property and equipment | (1,225,000) | (107,000) | — | — | — | — |
| Operating income (loss) | (3,823,000) | 1,115,000 | — | — | — | — |
| Interest expense | 6,744,000 | 7,168,000 | — | — | — | — |
| Interest income | (467,000) | (787,000) | — | — | — | — |
| Loss (gain) on foreign currency transactions | 367,000 | (43,000) | — | — | — | — |
| Share of loss in equity method investment | 324,000 | 309,000 | — | — | — | — |
| Change in fair value of derivative liability - interest rate swap | (452,000) | 1,122,000 | — | — | — | — |
| Loss before income taxes | (10,339,000) | (6,654,000) | — | — | — | — |
| Provision for income taxes | 241,000 | 109,000 | — | — | — | — |
| Net loss before noncontrolling interest | (10,580,000) | — | — | — | — | — |
| Net income attributable to noncontrolling interest | 121,000 | — | — | — | — | — |
| Net loss | (10,701,000) | (6,763,000) | — | — | — | — |
| Net income (loss) per share | ||||||
| Basic loss per share | (0.24) | (0.16) | — | — | — | — |
| Diluted loss per share | (0.24) | (0.16) | — | — | — | — |
| Weighted average number of common shares outstanding: | ||||||
| Basic (in shares) | 43,291 | 42,501 | — | — | — | — |
| Diluted (in shares) | 43,291 | 42,501 | — | — | — | — |
| Rentals of medical equipment | — | — | 96,237,000 | 69,192,000 | 55,338,000 | 41,251,000 |
| Sales of medical equipment and supplies | — | — | 125,505,000 | 70,670,000 | 47,013,000 | 31,388,000 |
| Total revenues | — | — | 221,742,000 | 139,862,000 | 102,351,000 | 72,639,000 |
| Cost of inventory sold | — | — | 57,897,000 | 33,213,000 | 28,172,000 | 19,934,000 |
| Operating expenses | — | — | 103,224,000 | 65,203,000 | 52,762,000 | 38,626,000 |
| Bad debt expense | — | — | 10,065,000 | 12,225,000 | — | — |
| Depreciation | — | — | 34,966,000 | 20,453,000 | 16,212,000 | 13,860,000 |
| Amortization of intangible assets | — | — | 5,197,000 | 2,587,000 | 1,574,000 | 678,000 |
| Stock-based compensation | — | — | 5,280,000 | 5,493,000 | 4,952,000 | 171,000 |
| Acquisition-related costs | — | — | 1,269,000 | 797,000 | 233,000 | 89,000 |
| Gain on sale of property and equipment | — | — | — | — | (94,000) | (74,000) |
| Loss (gain) on disposals of property and equipment | — | — | (75,000) | 45,000 | — | — |
| Other income from government grant | — | — | — | (4,885,000) | — | (1,303,000) |
| Operating income | — | — | 3,919,000 | 4,731,000 | (1,460,000) | 658,000 |
| Interest expense on leases and loans | — | — | — | 1,082,000 | — | — |
| Interest expense on convertible debenture | — | — | — | 609,000 | 838,000 | 887,000 |
| Interest expense on leases | — | — | — | — | 551,000 | 461,000 |
| Interest expense on loans | — | — | — | — | 376,000 | 489,000 |
| Amortization of financing costs | — | — | — | — | 140,000 | 5,000 |
| Interest expense, net | — | — | 6,607,000 | 388,000 | 88,000 | — |
| Loss on extinguishment of debt | — | — | 30,000 | 281,000 | — | — |
| (Gain) loss on foreign currency transactions | — | — | (108,000) | 144,000 | 173,000 | (454,000) |
| Transaction costs on issuance of financial liabilities | — | — | — | — | — | 210,000 |
| Change in fair value of warrants | — | — | — | — | 2,112,000 | 198,000 |
| Share of loss in equity method investment | — | — | 89,000 | — | — | — |
| Change in fair value of debentures | — | — | — | (1,150,000) | 3,591,000 | 2,437,000 |
| Loss on settlement of shares to be issued | — | — | — | 442,000 | — | — |
| Income (loss) before taxes | — | — | (2,699,000) | 2,935,000 | (9,329,000) | (3,575,000) |
| Provision (benefit) for income taxes | — | — | 85,000 | (1,904,000) | (3,155,000) | 128,000 |
| Net loss from continuing operations | — | — | — | — | (6,174,000) | (3,703,000) |
| Income (loss) from discontinued operations | — | — | — | — | — | (869,000) |
| Net income (loss) | — | — | (2,784,000) | 4,839,000 | (6,174,000) | (4,572,000) |
| Basic earnings per share | — | — | (0.07) | 0.14 | (0.20) | (0.20) |
| Diluted earnings per share | — | — | (0.07) | 0.13 | (0.20) | (0.20) |
| Basic | — | — | 38,607,000 | 33,647,000 | 30,438,000 | 22,721,000 |
| Diluted | — | — | 38,607,000 | 36,302,000 | 30,438,000 | 22,721,000 |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.